Qilian International Holding Group Limited logo
Qilian International Holding Group Limited QLI

Annual report 2021
added 10-13-2022

report update icon

Qilian International Holding Group Limited Accounts Receivables 2011-2026 | QLI

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.
Examples of accounts receivable
  • Customers have not paid invoices for delivered products
  • An advance has been paid to a supplier, but goods have not yet been received
  • Employees have not reported on accountable amounts
  • The government must refund tax overpayments
  • Outstanding loans issued
Importance of accounts receivable in company analysis
  1. Asset quality
    Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
  2. Impact on cash flow
    Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
  3. Assessment of management efficiency
    The following accounts receivable turnover ratios are commonly used:
    Receivables turnover = Revenue / Average accounts receivable
    (the higher — the better)

    Days Sales Outstanding (DSO) = 365 / Turnover
    (the fewer days — the faster customers pay)

    If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Qilian International Holding Group Limited

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.73 M 1.12 M - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.73 M 1.12 M 1.43 M

Quarterly Accounts Receivables Qilian International Holding Group Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - - - - 1.73 M - - - 1.12 M - - - 604 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
1.73 M 604 K 1.15 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer Accounts Receivables Price % 24h Market Cap Country
AgeX Therapeutics AgeX Therapeutics
AGE
57 K - -10.17 % $ 12.2 K usaUSA
I-Mab I-Mab
IMAB
130 M - - $ 866 M chinaChina
Esperion Therapeutics Esperion Therapeutics
ESPR
140 M $ 3.13 0.55 % $ 651 M usaUSA
Exelixis Exelixis
EXEL
287 M $ 48.2 8.51 % $ 13.1 B usaUSA
Fortress Biotech Fortress Biotech
FBIO
29.8 M $ 2.53 2.85 % $ 70.6 M usaUSA
Genmab A/S Genmab A/S
GMAB
34 M $ 27.95 1.5 % $ 17.2 B danmarkDanmark
Genprex Genprex
GNPX
34.9 K $ 0.91 2.24 % $ 849 K usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
38.4 M $ 231.58 -0.31 % $ 4.24 B usaUSA
INmune Bio INmune Bio
INMB
4.28 M $ 1.54 - $ 38.1 M usaUSA
Liquidia Corporation Liquidia Corporation
LQDA
54.1 M $ 41.64 3.75 % $ 3.58 B usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
98.7 M $ 22.58 1.03 % $ 3.74 B usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
123 M $ 107.36 1.46 % $ 5.39 B usaUSA
MannKind Corporation MannKind Corporation
MNKD
38.4 M $ 3.61 26.17 % $ 1.1 B usaUSA
Advaxis Advaxis
ADXS
234 K - -9.65 % $ 45.9 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
200 K - 1.93 % $ 17.4 M usaUSA
Aptinyx Aptinyx
APTX
257 K - -39.0 % $ 4.57 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
3.27 M - -0.23 % $ 916 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
146 M $ 24.0 2.46 % $ 3.05 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
392 K - - $ 2.17 B usaUSA